Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of MK-8527 in healthy adults
NCT06826989Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mk-8527 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Cumulative Percentage of Total Radioactivity Recovered (fe) from Urine and Feces up to 5 weeks, Fe from Urine up to 5 weeks and 20 more. Started Mar 2025; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06826989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826989.